Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease in which patients experience a progressive decline in lung function, worsening exercise capacity with increasing dyspnea and frequent exacerbations. 1, 2 COPD is a worldwide cause of morbidity and mortality which can be treated. Bronchodilator medications are considered central to the management of airway obstruction. Current treatment guidelines recommend the use of long-acting bronchodilators, either long-acting b 2 -agonist or anticholinergic, in symptomatic patients with moderate air-flow obstruction. 1, 2 Due to the long-term nature of the disease, it is important to consider clinical trials with prolonged durations of exposure to evaluate the impact of therapeutic interventions. Such long-term trials need to incorporate multiple measurements of efficacy in COPD including questionnaires such as the transition dyspnea index (TDI) 3 and the St George's Respiratory Questionnaire (SGRQ), 4 which are often used to measure dyspnea and health-related quality of life (HRQL). Similarly, the patient's use of rescue b 2 -agonist medication is often used as a surrogate for the degree to which patients are symptomatic due to air-flow limitation.
Tiotropium is an inhaled anticholinergic for the treatment of COPD that leads to bronchodilation for at least 24 hours with once-daily dosing. This sustained bronchodilation is due to the prolonged dissociation half life from the muscarinic M 3 receptor (approximately 35 h). 5 Two longterm, 1-year, placebo-controlled studies in the United States demonstrated that once-daily inhaled tiotropium consistently improved lung function, dyspnea, HRQL and rescue b 2 -agonist use compared with placebo over the course of the study. 6 In these studies, patients were invited to be evaluated one additional time 3 weeks after completing study medication. This follow-up visit provided a valuable opportunity to prospectively assess the extent to which patients were able to perceive the effects of treatment withdrawal and to evaluate the effects of tiotropium. In addition, this protocol provided outcome information regarding treatment withdrawal as a measure of treatment efficacy. Therefore, the purpose of this post-hoc analysis is to assess the effect of tiotropium withdrawal on dyspnea (TDI), health status (SGRQ), rescue b 2 -agonist use, and Peak Expiratory Flow Rate (PEFR).
Methods

Study patients
Two identical clinical trials designed to evaluate the efficacy and safety of tiotropium were combined and evaluated. The trials used a prospective, randomized, double-blind and parallel-group design. Tiotropium was administered at 18 mcg once daily via the HandiHaler â device (Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany). Fifty clinical centers participated in these trials and each center's institutional review board approved the protocol. All patients provided written informed consent prior to participation.
Inclusion and exclusion criteria have been fully described previously. 6 Briefly, the study groups consisted of outpatients of either gender who were at least 40 years of age with a clinical diagnosis of COPD, as defined by the American Thoracic Society. 7 Participants were required to have at least a 10-pack-year history of smoking, clinically stable airway obstruction, an FEV 1 less than 70% of the forced vital capacity (FVC) and a post-bronchodilator FEV 1 of less than 65% of the predicted normal value. Concomitant use of as-needed albuterol (by metered dose inhaler), theophylline (excluding 24-hour preparations), and inhaled steroids were allowed throughout the study period. The use of short-acting anticholinergics, oral b 2 -agonists, and longacting inhaled b 2 -agonists were not permitted during active treatment, but were allowed after study medication was withdrawn. Patients were excluded if they had a history of asthma, allergic rhinitis, atopy, or a total blood eosinophil count of more than 600/mm, required regular daytime supplemental oxygen, were on corticosteroid doses exceeding the equivalent of 10 mg of prednisone daily during the month prior to entering the study, had a recent history of myocardial infarction (1 year or less), hospitalization for heart failure (3 years or less), cardiac arrhythmias requiring drug therapy, symptomatic prostatic hypertrophy, or narrow angle glaucoma.
Study protocol
Following a two-week baseline period, patients were randomly assigned in a 3:2 ratio to receive either tiotropium (18 mg) or placebo. 6 Patients were administered active medication (tiotropium in lactose) or placebo (lactose) by inhalation, one dose each morning in identicalappearing capsules via a dry powder inhaler device (HandiHaler â ). Three weeks after completion of study medication, patients returned for a follow-up clinical assessment. During this follow-up period, there were no medication exclusions and tiotropium was not available at the time of the study. Dyspnea was assessed using the TDI, 3 health-related quality of life was measured using the SGRQ, 4 morning and evening Peak Expiratory Flow Rate (PEFR) was measured to provide an assessment of lung function, and rescue b 2 -agonist use over the 3-week followup period was recorded. For this study, we compared the clinical data obtained on the last study day to the 3-week follow-up visit data.
Statistical analysis
Data are presented as proportions or means (standard deviation). Analysis of covariance (ANCOVA) was used to compare the change in response over time in the two treatment groups for last treatment day and 3-week followup. Only those patients who had a valid baseline measurement and had at least some post-treatment data were included in the analysis. A TDI total score of at least one unit was considered a clinically significant change in activity-related dyspnea. 3 A change in SGRQ score of at least 4 units was considered to be a clinically significant change in quality of life. 4 Statistical significance was considered at p < 0.05.
Results
A total of 921 patients were enrolled (n Z 550 tiotropium; n Z 371 placebo) in these two clinical trials. 3 These post-hoc analyses include data from 713 patients (tiotropium Z 445, placebo 268) who have valid baseline measurements, completed the trial, and had 3-week post-treatment data. The baseline characteristics of the patients that completed the 3-weeks post-treatment evaluation between groups are similar ( Table 1) .
Because tiotropium was not commercially available at the time of the study, no patients were taking this medication at the 3-week post-treatment follow-up visit. In addition, there were no significant differences in respiratory medications at this final visit ( Table 2) .
Clinical parameters at last treatment day and 3-week follow-up are summarized in Table 3a and b. On the last treatment day, patients in the tiotropium group exhibited improvements in clinical parameters compared with patients in the placebo group. 3 The improvement from baseline in the morning and evening mean PEFR was significantly greater for the tiotropium-treated group vs. placebo on the last treatment day. The change from baseline of b 2 -agonist dose per week was À3.57 for the tiotropium-treated group and þ1.61 for the placebo group on the last treatment day. However, at the 3-week followup visit upon withdrawal of tiotropium, the mean scores were similar for both groups (Fig. 1A and B) . These values were þ0.70 for the tiotropium-discontinuation group vs. þ2.94 for the placebo-discontinuation group at the 3-week follow-up visit (Fig. 2) .
Assessment of dyspnea using TDI Focal scores is shown in Fig. 3 . A higher score denotes less dyspnea. Although the mean TDI Focal scores in the tiotropium-treated group are clinically and statistically higher than the placebo groups on the last treatment day (1.28 vs. 0.25, respectively; p < 0.001), the scores were similar at the 3-week discontinuation follow-up visit (0.20 for the tiotropiumdiscontinuation group vs. 0.39 for the placebo-discontinuation group). The mean change from baseline SGRQ Impacts and Total scores for the tiotropium and placebo groups on the last treatment day and at 3-week follow-up are shown in Fig. 4A and B. Lower values represent improved health status. Although not statistically significant, at the 3-week followup there was a trend towards improved mean SGRQ Total score (p Z 0.06) in the tiotropium-treated group.
Discussion
This secondary analysis from a prospective, randomized study demonstrates for the first time that there is no evidence of a rebound effect of dyspnea, PEFR, health status, or rescue b 2 -agonist use in patients with COPD three weeks after withdrawal of tiotropium. Patients in both study groups had similar dyspnea scores three weeks after the last treatment day. However, patients in the tiotropium-withdrawal group had trends towards improved health status, reduced b 2 -agonist use and better PEFRs compared with the placebo group despite discontinuation of active therapy for three weeks.
Bronchodilators are considered first-line therapy in the management of symptomatic COPD patients. 1, 2 Previously reported clinical trials have demonstrated that tiotropium improves lung function, dyspnea, exercise tolerance and health status. 6,8e11 In addition, clinical trials have shown consistent effects on reducing exacerbations of COPD. 12, 13 These effects are due in part to the prolonged dissociation half life from the muscarinic M 3 receptor (approximately 35 h), giving tiotropium a mean plasma half life of about one week. 5 In this study, we demonstrated that some of the tiotropium effects may be present for up to 3 weeks after discontinuation of therapy. The more relevant effects were highlighted that a significant number of patients enrolled in clinical trials of ICS in COPD have been conducted, at least, in part in patients already taking these medications. These investigators demonstrated a different clinical response in patients who continue to use ICS and patients that discontinue ICS. These analyses support prior reports of withdrawal effects after ICS are discontinued. Because these withdrawal effects of ICS were unexpected, documenting whether or not a similar phenomenon occurs upon the withdrawal of tiotropium is important. To our knowledge this is the first clinical report of the effect of tiotropium withdrawal. Our study demonstrates that dyspnea scores match the placebo group at three weeks after tiotropium withdrawal. However, those who were initially randomized to the active treatment group required less rescue use of b 2 -agonist and had better health-related quality of life scores three weeks after withdrawal of study medication. In addition, the worsening of symptoms in those withdrawn from tiotropium emphasizes the need for continuation of maintenance treatment.
There are several limitations to our analysis. Although, not all the patients that were randomized in the clinical trial completed the last treatment day and 3-week followup visit, we were able to obtain data in the majority of randomized patients. The 3-week follow-up period after withdrawal of study medication does not represent longterm follow-up; however, because the mean plasma half life of tiotropium is approximately one week and there may be sustained benefits on patient reported outcomes, changes in dyspnea, health status, PEFR, and rescue b 2 -agonist use can be evaluated within this period. Finally, spirometry was not obtained at the follow-up visit, although PEFR showed responsiveness to treatment and to withdrawal of treatment.
The evaluation of the withdrawal of active treatment is an effective technique for demonstrating the need for continued maintenance therapy. Our data demonstrate that some of the tiotropium effects on improved health status and reduced b 2 -agonist medication may be present for at least 3-weeks following discontinuation of therapy. These results warrant further investigation into the hypothesis that long-acting anticholinergics may have the potential to exert either direct or indirect long-term effects beyond smooth muscle relaxation in patients with COPD.
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